A CRA expert was retained in an antitrust class action matter on behalf of a branded pharmaceutical manufacturer in which plaintiffs alleged inappropriate listings of patents in the FDA’s Orange Book under the Hatch-Waxman Act, sham patent litigation, and attempted monopolization. CRA’s expert economic analyses demonstrated the branded pharmaceutical competed broadly with other products and that plaintiffs’ but-for model lacked validity.
Examining physician practice groups’ options to manage rising administrative and operational complexities
Charles River Associates (CRA) was commissioned by McKesson to analyze the economic role of McKesson’s Management Services Organizations (MSOs) within the...